The delivery of effective therapy to FGFR1-amplified lung SqCC appears to be much more complex than for EGFR-mutated or ALK-rearranged NSCLC where the genetic alteration highly predicts sensitivity to the associated targeted drug. Here, ALK is linked to non-small cell lung carcinoma.